| Merck & Company Inc. | Case 1 | | | Introduction of the Company Merck was established in 1891 to improve human and animal health through the development of innovative products. Merck currently has two reportable segments‚ the Pharmaceutical Segment and the Vaccines and Infectious Diseases Segment. Merck sells products through several channels including wholesalers‚ retailers‚ hospitals‚ clinics‚ government and managed health services providers. In the 1980’s the Merck was very
Premium Generic drug Pharmaceutical industry Mergers and acquisitions
MERCK: OPEN FOR INNOVATION? Founded in 1891 as an American subsidiary of his German namesake‚ Merck was once considered the “undisputed king of the pharmaceutical industry with ground‐ breaking drugs”(The Chief Executive 2003). But for the last decade‚ Merck has gone through a period of stagnation; it began to lose exclusivity patents on blockbuster drugs and has witnessed Pfizer’s rise to top place in the industry. It seemed now that internal R&D that was once the company’s main asset would
Premium Pharmaceutical industry
Executive Summary Merck & Company has been presented with an opportunity to invest $30 million for the purchasing rights of an obesity and high cholesterol lowering drug‚ KL-798 from Kappa Labs. Based on the expected probabilities of success through each product-development phase for this new drug‚ as well as the costs involved‚ the net present value of the project is -$1.16 million and is therefore recommended that Merck passes on the investment. Sensitivity analysis also show that adjusting
Premium Clinical trial Net present value Investment
Merck & Co.‚ Inc (A) (The summary is based on the article in Vol. I and does not include the extra readings given by the professor) This case is a classic example of enterprises trying to balance their business of increasing profits and expected social responsibilities. This dilemma is further accentuated when the company happens to be a pharma company whose decisions directly affect people’s lives. The Dilemma: A possible drug for River Blindness‚ a disease which affects almost 85 million
Premium Pharmacology Medicine Affect
Case #1: Merck and River Blindness MGT 597: Leadership Ethics Dr. Brandon Randolph-Seng Javiaur Harmon: Winter Mini 2014 - 2015 1. Think about the definition stakeholders—any parties with a stake in the organization’s actions or performance. Who are the stakeholders in this situation? How many can you list? On what basis would you rank them in importance? The stakeholders in this situation were the employees (research scientists doing the R&D)‚ Merck‚ and the target audience which
Premium Value system Risk Intrinsic value
Business and Professional Ethics MERCK AND THE MARKETING OF VIOXX – CASE ANALYSIS Questions 1) What are the highlights of the case? 2) What are the ethical issues in the case? 3) What the ethical theories evidenced in the case? 4) How would you resolve the problem? What are the ethical issues in the case? In identifying the issue(s) we first have to identify the level in which this business is operating. Merck & Company was a top‚ well respected pharmaceutical company in America
Premium Ethics
Merck and River Blindness (Onchocerciasis) In understanding the decision Merck made to donate medicines‚ we need to start by understanding the motivations and core values behind the company that undertook the actions. We can get some insight into these by examining and understanding their company mission statement: The mission of Merck is to provide society with superior products and services‚ innovations‚ and solutions that improve the quality of life and satisfy customer needs-to provide employees
Premium Water Water pollution Kidney
As a result of worldwide withdrawal of Vioxx‚ Merck faced a serious public relations crisis in the fall of 2004. Pharmaceutical giant’s officials were forced to defend company’s actions‚ its motivation for those actions‚ and its reputation after several articles‚ negatively reflecting on Merck’s behavior handling the Vioxx case‚ had been published. As an initial response to Vioxx crisis‚ the company released “An Open Letter from Merck” and “For 100 years‚ patients first” in attempt at a positive
Premium Pharmacology Pharmaceutical drug Drug
CEO Ray Gilmartin Merck’s CEO Ray Gilmartin is a significant stakeholder in the company. Since a lot of Mercks’ products patents will be expiring in the next few years Gilmartin put a big emphasis on investing into the companies research and development of new products. Gilmartin wanted this company to really focus on coming out with new products because their bottom line was going to take a hit in the next few years once the patent on their big money products runs out. Gilmartin found it an
Premium Pharmacology Finance Management occupations
research scientist working for Merck and Company‚ discovered evidence that one of the company’s drugs might kill the parasite that causes river blindness. He then decided to request permission to research this new finding. The mangers for the company noticed that it would take enormous amount of funding and time to develop this new vaccine. This new product could be really hard to market and who was going to actually buy it; it could also damaged the market share that Merck currently had by selling
Premium Medicine Science Physician